A randomized, placebo-controlled phase 2 study of ganitumab (AMG 479) or conatumumab (AMG 655) in combination with gemcitabine in patients with metastatic pancreatic cancer. [electronic resource]
Producer: 20130429Description: 2834-2842 p. digitalISSN:- 1569-8041
- Adenocarcinoma -- drug therapy
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal -- administration & dosage
- Antibodies, Monoclonal, Humanized
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Deoxycytidine -- administration & dosage
- Female
- Humans
- Male
- Middle Aged
- Neoplasm Metastasis -- drug therapy
- Pancreatic Neoplasms -- drug therapy
- Placebos
- Receptor, IGF Type 1 -- antagonists & inhibitors
- Survival Rate
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.